Skip to main content
AI Market Summary
Loading market intelligence...

Alexion Pharmaceuticals Inc. (ALXN) Stock Forecast 2025 - AI Price Prediction & Analysis


Alexion Pharmaceuticals Inc. (ALXN) AI Stock Price Forecast & Investment Analysis

Alexion Pharmaceuticals Inc. Stock Price Chart and Technical Analysis

Loading Alexion Pharmaceuticals Inc. interactive price chart and technical analysis...

Alexion Pharmaceuticals Inc. (ALXN) - Comprehensive Stock Analysis & Investment Research

Deep dive into Alexion Pharmaceuticals Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Alexion Pharmaceuticals Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Alexion Pharmaceuticals Inc.: Alexion Pharmaceuticals Inc. operates in the Manufacturing sector, positioning it as a large-cap market leader.

Alexion Pharmaceuticals Inc. (Stock Symbol: ALXN) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.

The organization employs approximately 2525 professionals worldwide and operates under the strategic leadership of CEO Ludwig Hantson.

The company has established itself as a major market leader with significant institutional backing.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Alexion Pharmaceuticals Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Alexion Pharmaceuticals Inc.: With $6262M in annual revenue and 10.9% net margin, the company demonstrates solid profitability.

Annual Revenue: $6262 million generating a 10.9% net profit margin .

Market Capitalization: $40515 million - Classified as a large-cap stock with institutional-grade stability.

Return on Equity (ROE): 5.6% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Alexion Pharmaceuticals Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Alexion Pharmaceuticals Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Alexion Pharmaceuticals Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Alexion Pharmaceuticals Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Alexion Pharmaceuticals Inc.: Strong free cash flow generation demonstrates exceptional operational efficiency.

Alexion Pharmaceuticals Inc. strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, positioning itself as a dominant large-cap market leader with significant competitive moats and institutional investor confidence .

The company demonstrates robust operational efficiency through strong free cash flow generation of $2866 million annually, complemented by impressive 44.0% year-over-year cash flow growth.

The company maintains a healthy 90.9% gross margin, indicating strong pricing power and operational efficiency.

Alexion Pharmaceuticals Inc. (ALXN) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Alexion Pharmaceuticals Inc. stock analysis.

Loading Alexion Pharmaceuticals Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Alexion Pharmaceuticals Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Alexion Pharmaceuticals Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Alexion Pharmaceuticals Inc.: With a P/E ratio of 59.25, the market highly values future growth prospects.

P/E Ratio 59.25x
P/B Ratio 0.16x
Market Cap $40515M
EPS $3.08
Book Value/Share $1131.58
Revenue/Share $28.21
FCF/Share $234.65
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Alexion Pharmaceuticals Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Alexion Pharmaceuticals Inc.: An ROE of 5.6% indicates room for improvement in shareholder value creation.

ROE 5.6%
ROA 3.7%
ROIC 5.1%
Gross Margin 90.9%
Operating Margin 47.1%
Net Margin 10.9%
EBT Margin 8.1%
Tax Rate 68.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Alexion Pharmaceuticals Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Alexion Pharmaceuticals Inc.: A current ratio of 4.52 indicates strong liquidity.

Current Ratio 4.52x
Quick Ratio 3.47x
D/E Ratio 0.21x
Financial Leverage 1.50x
Interest Coverage 5.8x
Working Capital $4208M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Alexion Pharmaceuticals Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Alexion Pharmaceuticals Inc.: Free cash flow of $2866M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $3091M
Free Cash Flow $2866M
Capital Spending $-224M
OCF Growth YoY 44.0%
FCF Growth YoY 51.3%
FCF/Sales 45.8%
CapEx/Sales 3.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Alexion Pharmaceuticals Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Alexion Pharmaceuticals Inc.: An asset turnover of 0.34x suggests room for improvement in asset utilization.

Asset Turnover 0.34x
Receivables Turnover 4.4x
Inventory Turnover 0.8x
Fixed Assets Turnover 4.4x
Days Sales Outstanding 82 days
Days Inventory 447 days
Payables Period 81 days
Cash Conversion Cycle 449 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Alexion Pharmaceuticals Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Alexion Pharmaceuticals Inc.: With annual revenue of $6262M, Alexion Pharmaceuticals Inc. operates at significant scale.

Income Statement ($ Millions)
Total Revenue $6262M
Operating Income $2947M
Net Income $681M
R&D Expense $17M
SG&A Expense $23M
Cost of Goods Sold $9M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 35%
Cash & Short-term Investments 19%
Total Liabilities 33%
Short-term Debt 1%
Accounts Receivable 8%
Inventory 4%
Dividend & Shareholder Information
Shares Outstanding 222M

Latest Alexion Pharmaceuticals Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Alexion Pharmaceuticals Inc. (ALXN) stock price and investment outlook.

, source: Benzinga.com

Who is ALEXION PHARMACEUTICALS, INC.? ALEXION PHARMACEUTICALS, INC. has an estimated net worth of $5.53 Million. This is based on reported shares across multiple companies, which include Inozyme ...

, source: Hartford Business

Two pioneers of the Elm City’s bioscience industry are about to become one. Alexion Pharmaceuticals Inc. said Wednesday morning it plans to acquire fellow New Haven-born drugmaker Achillion ...

Alexion Pharmaceuticals Inc. Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Alexion Pharmaceuticals Inc. against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Alexion Pharmaceuticals Inc. Stock Forecast

How accurate are Alexion Pharmaceuticals Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for ALXN predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Alexion Pharmaceuticals Inc. stock price forecasts?

Our analysis considers Alexion Pharmaceuticals Inc.'s financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Alexion Pharmaceuticals Inc. a good investment in 2025?

Based on our AI analysis, Alexion Pharmaceuticals Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Alexion Pharmaceuticals Inc. forecasts updated?

Alexion Pharmaceuticals Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Alexion Pharmaceuticals Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Alexion Pharmaceuticals Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...